Inscription - Connexion

Se souvenir de moi

Index » Droit des sociétés » Corporate Law & Governance Update » Envoyer le lien

Voir le sujet précédent :: Voir le sujet suivant  
Message Posté par davefollmers le Ven Avr 13, 2018 13:00 Répondre en citant

Several new developments highlight the special oversight obligations of directors in connection with health system investment in new technology ventures.
For example, a recent article in The Wall Street Journal, Hospitals Gamble on Start-Ups,” provides an interesting overview of the technology investment activities of several leading national nonprofit health systems, with particular focus on “start up” enterprises and other creative approaches. System leaders describe such investments as strategic in nature, with favorable implications for patient care and financial return.
However, these innovation ventures will often benefit from specialized director oversight at the health system level; i.e., independent, conflict-free board or committee members who have familiarity with the financial and operational characteristics of these types of investments, and thus may be more capable of tracking results and spotting “red flags.” Such specialized directors can be expected to be increasingly in demand by boards.
The value of such specialized oversight is underscored by the ongoing Theranos controversy, in which prominent and respected individuals (e.g., General James Mattis and George Shultz) were heavily criticized for their alleged failure to identify the extent to which technological problems with the company’s blood testing technology would affect its business model feasibility.

For More You Can Check:
Creative Promotional Examples
Revenir en haut Voir le profil de l'utilisateur Envoyer un message privé
Montrer les messages depuis:   

Nouveau message | Répondre

Index » Droit des sociétés » Corporate Law & Governance Update » Envoyer le lien

Sauter vers: